Tryptophan: The key to boosting brain serotonin synthesis in depressive Illness

Journal of Psychopharmacology

Volumn 27, Issue 10, 2013, Pages 878-893

  Badawy, Abdulla A B ^a  

^a CARDIFF METROPOLITAN UNIVERSITY   (United Kingdom)

Author keywords

Adrenal medullary hormones; antidepressants; cortisol; depression; immune activation; nonesterified fatty acids; serotonin; tryptophan; tryptophan dioxygenase

Indexed keywords

5 HYDROXYTRYPTOPHAN; ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CATECHOLAMINE; CYTOKINE; DESIPRAMINE; ESTROGEN; FLUOXETINE; GAMMA INTERFERON; HYDROCORTISONE; HYPERICUM PERFORATUM EXTRACT; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; LOFEPRAMINE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; PAROXETINE; PROGESTERONE; SALICYLIC ACID; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN; TRYPTOPHAN 2,3 DIOXYGENASE; TRYPTOPHAN HYDROXYLASE; TRYPTOPHAN HYDROXYLASE 2;

ADRENAL MEDULLA; AMINO ACID SYNTHESIS; BRAIN LEVEL; CYTOKINE PRODUCTION; DEPRESSION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME STABILITY; ENZYME SUBSTRATE; HUMAN; IN VITRO STUDY; LOADING DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; UNSPECIFIED SIDE EFFECT;

ADRENAL MEDULLARY HORMONES; ANTIDEPRESSANTS; CORTISOL; DEPRESSION; IMMUNE ACTIVATION; NONESTERIFIED FATTY ACIDS; SEROTONIN; TRYPTOPHAN; TRYPTOPHAN DIOXYGENASE;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSIVE DISORDER, MAJOR; HUMANS; SEROTONIN; TRYPTOPHAN; TRYPTOPHAN HYDROXYLASE; TRYPTOPHAN OXYGENASE;

EID: 84883881295     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113499209     Document Type: Review

References (173)

1. Altman K, Greengard O. Correlation of kynurenine excretion with liver tryptophan pyrrolase levels in disease and after hydrocortisone induction. J Clin Invest. 1966 ; 45: 1527-1534
2. Anderson IM. Meta-Analytical studies on new antidepressants. Br Med Bull. 2001 ; 57: 161-178
3. Anisman H, Merali Z. Cytokines, stress and depressive illness. Brain Behav Immunity. 2002 ; 16: 513-524
4. Assies J, Pouwer F, Lok A, et al. Plasma and erythrocyte fatty acid patterns in patients with recurrent depression: A matched case-control study. PLoS. 2010 ; 5: e10635
5. Azmitia EC, McEwen BS. Early response of rat brain tryptophan hydroxylase activity to cycloheximide, puromycin and corticosterone. J Neurochem. 1976 ; 27: 773-778
6. Badawy A.A.-B. Mechanisms of elevation of rat brain tryptophan concentration by various doses of salicylate. Br J Pharmacol. 1982 ; 76: 211-213
7. Badawy A.A.-B. Effects of pregnancy on tryptophan metabolism and disposition in the rat. Biochem J. 1988 ; 255: 369-372
8. Badawy A.A.-B. Tryptophan metabolism in alcoholism. Nutr Res Rev. 2002 ; 15: 123-152
9. Badawy A.A.-B. Perspective: Plasma free tryptophan revisited: What you need to know and do before measuring it. J Psychopharmacol. 2010 ; 24: 809-815
10. Badawy AA-B, Evans M. The mechanism of inhibition of rat liver tryptophan pyrrolase activity by 4-hydroxypyrazolo[3,4-d]pyrimidine (allopurinol). Biochem J. 1973 ; 133: 585-591
11. Badawy AA-B, Evans M. Tryptophan plus a pyrrolase inhibitor for depression?. Lancet. 1974 ; ii: 1209-1210
12. Badawy AA-B, Evans M. The regulation of rat liver tryptophan pyrrolase by its cofactor haem - experiments with haematin and 5-Aminolaevulinate and comparison with the substrate and hormonal mechanisms. Biochem J. 1975a ; 150: 511-520
13. Badawy AA-B, Evans M. Tryptophan plus a pyrrolase inhibitor for depression. Lancet. 1975b ; ii: 869
14. Badawy AA-B, Evans M. The regulation of rat liver tryptophan pyrrolase activity by reduced nicotinamide-Adenine dinucleotide (phosphate): Experiments with glucose and nicotinamide. Biochem J. 1976a ; 156: 381-390
15. Badawy AA-B, Evans M. Animal liver tryptophan pyrrolases - absence of apoenzyme and of hormonal induction mechanism from species sensitive to tryptophan toxicity. Biochem J. 1976b ; 158: 79-88
16. Badawy AA-B, Evans M. The role of free serum tryptophan in the biphasic effect of acute ethanol administration on the concentrations of rat brain tryptophan, 5-hydroxytryptamine and 5-hydroxyindol-3-ylacetic acid. Biochem J. 1976c ; 160: 315-324
17. Badawy AA-B, Evans M. Inhibition of rat liver tryptophan pyrrolase activity and elevation of brain tryptophan concentration by administration of antidepressants. Biochem Pharmacol. 1981 ; 30: 1211-1216
18. Badawy AA-B, Evans M. Inhibition of rat liver tryptophan pyrrolase activity and elevation of brain tryptophan concentration by acute administration of small doses of antidepressants. Br J Pharmacol. 1982 ; 77: 59-67
19. Badawy AA-B, Evans M. Opposite effects of chronic administration and subsequent withdrawal of drugs of dependence on the metabolism and disposition of endogenous and exogenous tryptophan in the rat. Alcohol Alcohol. 1983 ; 18: 369-382
20. Badawy AA-B, Morgan CJ. Tryptophan and tryptophan pyrrolase in haem regulation: The role of lipolysis and direct displacement of serum-protein-bound tryptophan in the opposite effects of administration of endotoxin, morphine, palmitate, salicylate and theophylline on rat liver 5-Aminolaevulinate synthase activity and the haem saturation of tryptophan pyrrolase. Biochem J. 1982 ; 206: 451-460
21. Badawy AA-B, Morgan CJ. Effects of acute paroxetine administration on tryptophan metabolism and disposition in the rat. Br J Pharmacol. 1991 ; 102: 429-433
22. Badawy AA-B, Smith MJH. The effects of salicylate in the activity of rat liver tryptophan pyrrolase in vitro and in vivo. Biochem J. 1971 ; 123: 171-174
23. Badawy AA-B, Dougherty DM, Richard DM. Specificity of the acute tryptophan and tyrosine plus phenylalanine depletion and loading tests. I Review of biochemical aspects and poor specificity of current amino acid formulations. Int J Tryptophan Res. 2010 ; 3: 23-34
24. Badawy AA-B, Morgan CJ, Bano S, et al. Mechanism of enhancement of rat brain serotonin synthesis by acute fluoxetine administration. J Neurochem. 1996 ; 66: 436-437
25. Badawy AA-B, Morgan CJ, Dacey A, et al. The effects of lofepramine and desmethylimipramine on tryptophan metabolism and disposition in the rat. Biochem Pharmacol. 1991 ; 42: 921-929
26. Badawy AA-B, Morgan CJ, Gordon CA. Mechanism of action of mood stabilisers: Transient inhibition of liver tryptophan pyrrolase activity by acute administration of carbamazepine and lithium. J Psychopharmacol. 1989a ; 3: 82P
27. Badawy AA-B, Morgan CJ, Gordon CA. Effects of carbamazepine on tryptophan metabolism and disposition in the rat. Br J Pharmacol. 1989b ; 98: 614P
28. Badawy AA-B, Punjani NF, Evans M. The effects of ethanol on rat liver and brain tryptophan metabolism. Subst Alcohol Actions Misuse. 1980a ; 1: 507-515
29. Badawy AA-B, Punjani NF, Evans CM, et al. Inhibition of rat brain tryptophan metabolism by ethanol withdrawal and possible involvement of the enhanced liver tryptophan pyrrolase activity. Biochem J. 1980b ; 192: 449-455
30. Bano S, Gitay M, Ara I, et al. Acute effects of serotonergic antidepressants on tryptophan metabolism and corticosterone levels in rats. Pak J Pharm Sci. 2010 ; 23: 266-272
31. Bano S, Toor M, Morgan CJ, et al. Inhibition of rat liver tryptophan pyrrolase activity by acamprosate, moclobemide, roxindole, SSRIs and tianeptine. J Psychopharmacol. 1995 ; 9: A23
32. Barden N, Reul JM, Holsboer F. Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-Adrenocortical system?. Trends Neurosci. 1995 ; 18: 6-11
33. Bellodi L, Erzegovesi S, Bianchi L, et al. Plasma tryptophan levels and tryptophan/neutral amino acid ratios in obsessive-compulsive patients with and without depression. Psychiatry Res. 1997 ; 69: 9-15
34. Bender DA. Biochemistry of tryptophan in health and disease. Mol Aspects Med. 1982 ; 6: 101-197
35. Berney A, Nishikawa M, Benkelfat C, et al. An index of 5-HT synthesis changes during early antidepressant treatment: alpha-[11C] methyl-L-tryptophan PET study. Neurochem Int. 2008 ; 52: 701-708
36. Blier P, de Montigny C. Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology. 1999 ; 21: 91S - 98S
37. Brattsand R, Linden M. Cytokine modulation by glucocorticoids: Mechanisms and actions in cellular studies. Aliment Pharmacol Ther. 1996 ; 10: 81-90
38. Brown RR, Lee CM, Kohler PC, et al. Altered tryptophan and neopterin metabolism in cancer patients treated with recombinant interleukin 2. Cancer Res. 1989 ; 49: 4941-4944
39. Carlin JM, Borden EC, Sondel PM, et al. Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes. J Leukoc Biol. 1989 ; 45: 29-34
40. Chiarugi A, Rovida E, Dello Sbarba P, et al. Tryptophan availability selectively limits NO-synthase induction in macrophages. J Leukoc Biol. 2003 ; 73: 172-177
41. Chouinard G, Young SN, Annable L, et al. Tryptophan-nicotinamide, imipramine and their combination in depression. Acta Psychiatr Scand. 1979 ; 59: 395-414
42. Colmenares JL, Wurtman RJ. The relation between urinary 5-hydroxyindoleacetic acid levels and the ratio of tryptophan to other large neutral amino acids placed in the stomach. Metabolism. 1979 ; 28: 820-827
43. Cook EH, Anderson GM, Heninger GR, et al. Tryptophan loading in hyperserotonemic and normoserotonemic adults. Biol Psychiatry. 1992 ; 31: 525-528
44. Cook JS, Pogson CI, Smith SA. Indoleamine 2,3-dioxygenase: A new, rapid, sensitive radiometric assay and its application to the study of the enzyme in rat tissues. Biochem J. 1980 ; 189: 461-466
45. Cowen PJ. The role of 5-HT in the action of antidepressant drugs. Pharmacol Ther. 1990 ; 46: 43-51
46. Cowen PJ, Parry-Billings M, Newsholme EA. Decreased plasma tryptophan levels in major depression. J Affect Disord. 1989 ; 16: 27-31
47. Curzon G. Tryptophan pyrrolase-A biochemical factor in depressive illness?. Br J Psychiatry. 1969 ; 115: 1367-1374
48. Curzon G. Relationship between plasma, CSF and brain tryptophan. J Neural Transm. 1979a ; 15: 81-92
49. Curzon G. Study of disturbed tryptophan metabolism in depressive illness. Ann Biol Clinique. 1979b ; 37: 27-33
50. Curzon G, Green AR. Effect of hydrocortisone on rat brain 5-hydroxytryptamine. Life Sci. 1968 ; 7: 657-663
51. Curzon G, Knott PJ. Effects on plasma and brain tryptophan in the rat of drugs and hormones that influence the concentration of unesterified fatty acids in the plasma. Br J Pharmacol. 1974 ; 50: 197-204
52. Däubner W, MacKenzie CR. Interferon-γ activated indoleamine 2,3-dioxygenase activity in human cells is an antiparasitic and antibacterial effector mechanism. Adv Exp Med Biol. 1999 ; 467: 517-524
53. De Abajo FJ, Rodriguez LAG, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: Population based case-control study. Br Med J. 1999 ; 319: 1106-1109
54. De Jong JCF, van den Berg PB, Tobi H, et al. Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. Br J Clin Pharmacol. 2003 ; 55: 591-595
55. Delgado PL, Charney DS, Price LH, et al. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry. 1990 ; 47: 411-418
56. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-Analysis of cytokines in major depression. Biol Psychiatry. 2010 ; 67: 446-457
57. Fernstrom JD, Wurtman RJ. Brain serotonin content: physiological dependence on plasma tryptophan levels. Science. 1971 ; 173: 149-152
58. Franzone JS, Caravanzola C, Reboani MC. Influence of non-steroidal anti-inflammatory compounds on the hepatic tryptophan pyrrolase activity in hypo- and hyperthyroid rats. Arch Int Pharmacodyn Ther. 1980 ; 245: 156-165
59. Fuchs D, Forsman A, Hagberg L, et al. Immune activation and decreased tryptophan in patients with HIV-1 infection. J Interferon Res. 1990 ; 10: 599-603
60. Gagne D, Pons M, Philibert D. RU 38486: A potent antiglucocorticoid in vitro and in vivo. J Steroid Biochem. 1985 ; 23: 247-251
61. Gál EM. Tryptophan 5-hydroxylase: function and control. Adv Biochem Psychopharmacol. 1974 ; 11: 1-11
62. Gál EM, Young RB, Sherman AD. Tryptophan loading: Consequent effects on the synthesis of kynurenine and 5-hydroxyindoles in rat brain. J Neurochem. 1978 ; 31: 237-244
63. Gallagher P, Malik N, Newham J, et al. Antiglucocorticoid treatments for mood disorders. Cochrane Database Syst Rev Jan. 2008 ; 23 (1). CD005168
64. Gentil V, Lader MH, Kantamanini BD, et al. Effects of adrenaline injection on human plasma tryptophan and non-esterified fatty acids. Clin Sci Mol Med. 1977 ; 53: 227-232
65. Gjerde H, Mørland J, Olsen H. The antiglucocorticoid RU486 inhibits the ethanol-induced increase in tryptophan oxygenase. J Steroid Biochem. 1985 ; 23: 1091-1092
66. Gourion D. Antidepressants and their onset of action: A major clinical, methodological and prognostical issue. Encephale. 2008 ; 34: 73-81
67. Green AR, Aronson JK. Metabolism of an oral tryptophan load II1: Effect of a pyridoxine supplement. Br J Clin Pharmacol. 1980 ; 10: 617-619
68. Green AR, Curzon G. Decrease of 5-hydroxytryptamine in the brain provoked by hydrocortisone and its prevention by allopurinol. Nature. 1968 ; 220: 1095-1097
69. Green AR, Aronson JK, Cowen PJ. The pharmacokinetics of L-tryptophan following its intravenous and oral administration. Br J Clin Pharmacol. 1985 ; 20: 317-321
70. Green AR, Aronson JK, Curzon G, et al. Metabolism of an oral tryptophan load: 1. Effects of dose and pretreatment with tryptophan. Br J Clin Pharmacol. 1980 ; 10: 603-610
71. Green AR, Bloomfield MR, Woods HF, et al. Metabolism of an oral tryptophan load by women and evidence against the induction of tryptophan pyrrolase by oral contraceptives. Br J Clin Pharmacol. 1978 ; 5: 233-241
72. Green AR, Woods HF, Knott PJ, et al. Factors influencing effect of hydrocortisone on rat brain tryptophan metabolism. Nature. 1975 ; 255: 170
73. Gregoire AJ, Kumar R, Everitt B, et al. Transdermal oestrogen for treatment of severe postnatal depression. Lancet. 1996 ; 347: 930-933
74. Hannestad J, Della Gioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: A meta-Analysis. Neuropsychopharmacology. 2011 ; 36: 2452-2459
75. Harmer CJ, Goodwin GM, Cowen PJ. Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br J Psychiatry. 2009 ; 195: 102-108
76. Hashioka S, Klegeris A, Monji A, et al. Antidepressants inhibit interferon-gamma-induced microglial production of IL-6 and nitric oxide. Exp Neurol. 2007 ; 206: 33-42
77. Hayaishi O. Properties and functions of indoleamine 2,3-dioxygenase. J Biochem (Tokyo). 1976 ; 79: 13P - 21P
78. Herrington RN, Bruce A, Johnstone EC, et al. Comparative trial of L-tryptophan and amitriptyline in depressive illness. Psychol Med. 1976 ; 6: 673-678
79. Hirota T, Hirota K, Sanno Y, et al. Appearance of new hepatic glucocorticoid binding proteins under various stressful conditions: Relation to endogenous glucocorticoid secretion. J Biochem (Tokyo). 1985a ; 97: 1371-1376
80. Hirota T, Hirota K, Sanno Y, et al. A new glucocorticoid receptor species: Relation to induction of tryptophan dioxygenase by glucocorticoids. Endocrinology. 1985b ; 117: 1788-1795
81. Howes OD, Kambeitz J, Kim E, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment - Meta-Analysis of imaging studied. Arch Gen Psychiatry. 2012 ; 69: 776-786
82. Hucke C, MacKenzie CR, Adjogble KDZ, et al. Nitric oxide-mediated regulation of gamma interferon-induced bacteriostasis: Inhibition and degradation of human indoleamine 2,3-dioxygenase. Infect Immun. 2004 ; 72: 2723-2730
83. Johnson DA, Grant EJ, Ingram CD, et al. Glucocorticoid receptor antagonists hasten and augment neurochemical responses to a selective serotonin reuptake inhibitor antidepressant. Biol Psychiatry. 2007 ; 62: 1228-1235
84. Joseph MH, Young SN, Curzon G. The metabolism of a tryptophan load in rat brain and liver: The influence of hydrocortisone and allopurinol. Biochem Pharmacol. 1976 ; 25: 2599-2604
85. Karuppaswamy J, Vlies R. The benefit of oestrogens and progestogens in postnatal depression. J Obstet Gyn. 2003 ; 23: 341-346
86. Keating C, Tilbrook A, Kulkami J. Oestrogen: An overlooked mediator in the neuropsychopharmacology of treatment response?. Int J Neuropsychopharmacol. 2011 ; 14: 553-566
87. Ketterer MW, Brymer J, Rhoads K, et al. Is aspirin, as used for antithrombosis, an emotion-modulating agent. J Psychosom Res. 1996 ; 40: 53-58
88. Knitza R, Clasen R, Kunz C. Serum concentrations of non esterified fatty acids during operative stress and blockade of betaadrenergic receptors. Klin Wochenschr. 1978 ; 56: 1085-1087
89. Landmann R, Schaub B, Link S, et al. Unaltered monocyte function in patients with major depression before and after three months of antidepressive therapy. Biol Psychiatry. 1997 ; 41: 675-681
90. Lapin IP, Oxenkrug GF. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet. 1969 ; i: 132-136
91. Leonard BE. Clinical implications of mechanisms of action of antidepressants. Adv Psychiatr Treatment. 2000 ; 6: 178-186
92. Levitan RD, Shen JH, Jindal R, et al. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: Antidepressant and hypnotic effects. J Psychiatry Neurosci. 2000 ; 25: 337-346
93. Linkowski P, Mendlewicz J, Kerkhofs M, et al. 24-hour profiles of adrenocorticotropin, cortisol, and growth hormone in major depressive illness: Effect of antidepressant treatment. J Clin Endocrinol Metab. 1987 ; 65: 141-152
94. Lucca A, Lucini V, Catalano M, et al. Plasma tryptophan to large neutral amino acids ratio and therapeutic response to a selective serotonin uptake inhibitor. Neuropsychobiology. 1994 ; 29: 108-111
95. Lucini V, Lucca A, Catalano M, et al. Predictive value of tryptophan/large neutral amino acids ratio to antidepressant response. J Affect Disord. 1996 ; 36: 129-133
96. MacGillivray S, Arroll B, Hatcher S, et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: Systematic review and meta-Analysis. Br Med J. 2003 ; 326: 1014.1
97. Machado-Vieira R, Baumann J, Wheeler-Castillo C, et al. The timing of antidepressant effects: A comparison of diverse pharmacological and somatic treatments. Pharmaceuticals. 2010 ; 3: 19-41
98. MacKenzie CR, González RG, Kniep E, et al. Cytokine mediated regulation of interferon-gamma-induced IDO activation. Adv Exp Med Biol. 1999 ; 467: 533-539
99. Maes MHJ, De Ruyter M, Suy E. Prediction of subtype and severity of depression by means of dexamethasone suppression test, L-tryptophan:competing amino acid ratio, and MHPG flow. Biol Psychiatry. 1987 ; 22: 177-188
100. Maes M, Jacobs M-P, Suy E, et al. Effects of dexamethasone on the availability of L-tryptophan and on the insulin and FFA concentrations in unipolar depressed patients. Biol Psychiatry. 1990a ; 27: 854-862
101. Maes M, Scharpe S, Meltzer HY, et al. Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: Further evidence for an immune response. Psychiatry Res. 1994 ; 54: 143-160
102. Maes M, Vandewoude M, Schott C, et al. The decreased availability of L-tryptophan in females: Clinical and biological correlates. Prog Neuropsychopharmacol Biol Psychiatry. 1990b ; 14: 903-919
103. Manjunath R, Ramasarma T. Stimulation of liver tryptophan pyrrolase during heat exposure. Biochem J. 1985 ; 226: 397-402
104. Matsuda J, Gohchi K, Gotoh N. Serum concentrations of 2',5'-oligoadenylate synthetase, neopterin and beta-glucan in patients with chronic fatigue syndrome and in patients with major depression. J Neurol Neurosurg Psychiatry. 1994 ; 57: 1015-1016
105. Mauri MC, Boscati L, Volonteri LS, et al. Predictive value of amino acids in the treatment of major depression with fluvoxamine. Neuropsychobiology. 2001 ; 44: 134-138
106. McKinney J, Knappskog PM, Haavik J. Different properties of the central and peripheral forms of human tryptophan hydroxylase. J Neurochem. 2005 ; 92: 311-320
107. Meek JL, Neff HN. Tryptophan hydroxylase: Approximation of half-life and rate of axonal transport. J Neurochem. 1972 ; 19: 1519-15325
108. Meltzer HY. Serotonergic function in the affective disorders: The effect of antidepressants and lithium on the 5-hydroxytryptophan-induced increase in serum cortisol. Ann NY Acad Sci. 1984 ; 430: 115-137
109. Meltzer HY, Lowy MT Psychopharmacology: The Third Generation of Progress. Meltzer HY, ed. New York: Raven Press ; 1987: 513-526.
110. Meltzer H, Bastani B, Jayathilake K, et al. Fluoxetine, but not tricyclic antidepressants, potentiates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder. Neuropsychopharmacology. 1997 ; 17: 1-11
111. Mendelwicz J, Kriwin P, Oswald P, et al. Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: A pilot open-label study. Int Clin Psychopharmacol. 2006 ; 21: 227-231
112. Menna-Perper M, Rochford J, Mueller PS, et al. Differential response of plasma glucose, amino acids and nonesterified fatty acids to insulin in depressed patients. Psychoneuroendocrinology. 1984 ; 9: 161-171
113. Mennini T, Mocaer E, Garattini S. Tianeptine, a selective enhancer of serotonin uptake in rat brain. Naunyn Schmiedeberg's Arch Pharmacol. 1987 ; 336: 478-482
114. Miller HL, Delgado PL, Salomon RM, et al. Acute tryptophan depletion: A method of studying antidepressant action. J Clin Psychiatry. 1992 ; 53: 28-35
115. Møller SE. Tryptophan to competing amino acid ratio in depressive disorder: Relation to efficacy of antidepressive treatments. Acta Psychiatr Scand Suppl. 1985 ; 325: 3-31
116. Møller S, Reisby N, Ortmann J, et al. Relevance of tryptophan and tyrosine availability in endogenous and 'non-endogenous' depressives treated with imipramine or clomipramine. J Affect Disord. 1981 ; 3: 231-244
117. Møller SE, Honoré P, Larsen OB. Tryptophan and tyrosine ratios to neutral amino acids in endogenous depression: Relation to antidepressant response to amitriptyline and lithium + L-tryptophan. J Affect Disord. 1983 ; 5: 67-79
118. Møller SE, Bech P, Bjerrum H, et al. Plasma ratio of tryptophan/neutral amino acids in relation to clinical response to paroxetine and clomipramine in patients with major depression. J Affect Disord. 1990 ; 18: 59-66
119. Møller SE, de Beurs P, Timmerman L, et al. Plasma tryptophan and tyrosine ratios to competing amino acids in relation to antidepressant response to citalopram and maprotiline: A preliminary study. Psychopharmacology. 1986 ; 88: 96-100
120. Montgomery SA, Bech P, Blier P, et al. Selecting methodologies for the evaluation of differences in time to response between antidepressants. J Clin Psychiatry. 2002 ; 63: 694-699
121. Murphy KL, Zhang X, Gainetdinov RR, et al. A regulatory domain in the N terminus of tryptophan hydroxylase 2 controls enzyme expression. J Biol Chem. 2008 ; 283: 13216-13224
122. Nolen WA, Van De, Putte JJ, Dijken WA, et al. L-5HTP in depression resistant to re-uptake inhibitors: An open comparative study with tranylcypromine. Br J Psychiatry. 1985 ; 147: 16-22
123. O'Toole SM, Chiapelli F, Rubin RT. Plasma neopterin in major depression: Relationship to basal and stimulated pituitary-Adrenal cortical axis function. Psychiatry Res. 1998 ; 79: 21-29
124. Ozaki Y, Edelstein MP, Duch DS. The actions of interferon and antiinflammatory agents on induction of indoleamine 2,3-dioxygenase in human peripheral blood monocytes. Biochem Biophys Res Commun. 1987 ; 144: 1147-1153
125. Pariante CM, Thomas SA, Lovestone S, et al. Do antidepressants regulate how cortisol affects the brain?. Psychoneuroendocrinology. 2004 ; 29: 423-447
126. Peretti CS, Martin P, Bayle F, et al. Definitions and recommendations for studying the delay of antidepressant action. Part 3: Methodological aspects. Encephale. 2003 ; 29: 313-321
127. Perret G, Hilleret H, Widmer JR, et al. L-tryptophan plasma levels in treatment resistant depressive states. Rev Med Suisse Romande. 2000 ; 120: 153-157
128. Pfefferkorn ER, Rebhun S, Eckel M. Characterisation of an indoleamine dioxygenase induced by gamma interferon in cultured human fibroblasts. J Interferon Res. 1986 ; 6: 267-279
129. Plihal W, Krug R, Pietrowsky R, et al. Corticosteroid receptor mediated effects on mood in humans. Psychoneuroendocrinology. 1996 ; 21: 515-523
130. Post RM Psychopharmacology: The Third Generation of Progress. Meltzer HY, ed. New York: Raven Press ; 1987: 567-576.
131. Quintana J. Platelet serotonin and plasma tryptophan decreases in endogenous depression. Clinical, therapeutic and biological correlates. J Affect Disord. 1992 ; 24: 55-62
132. Richard DM, Dawes MA, Mathias CW, et al. L-Tryptophan: basic metabolic functions, behavioral research and therapeutic indications. Int J Tryptophan Res. 2009 ; 2: 45-60
133. Russ MJ, Ackerman SH, Banay-Schwartz M, et al. Plasma tryptophan to large neutral amino acid ratios in depressed and normal subjects. J Affect Disord. 1990 ; 19: 9-14
134. Saeed S, Bano S. Inhibition of tryptophan pyrrolase activity in restraint female rats following medroxyprogesterone administration. J Coll Physicians Surg Pak. 2007 ; 17: 63-68
135. Saito K, Seishima M, Noma A, et al. Cytokine and drug modulation of kynurenine pathway metabolism by blood mononuclear cells. Adv Exp Med Biol. 1996 ; 398: 161-165
136. Salter M, Hazelwood R, Pogson CI, et al. The effects of a novel and selective inhibitor of tryptophan 2,3-dioxygenase on tryptophan and serotonin metabolism in the rat. Biochem Pharmacol. 1995a ; 49: 1435-1442
137. Salter M, Hazelwood R, Pogson CI, et al. The effects of an inhibitor of tryptophan 2,3-dioxygenase and a combined inhibitor of tryptophan 2,3-dioxygenase and 5-HT reuptake in rats. Neuropharmacology. 1995b ; 34: 217-227
138. Samsonova ML, Lapin IP. Antidepressants and liver tryptophan pyrrolase activity. Biochem Pharmacol. 1973 ; 22: 1499-1507
139. Scharnholz B, Weber-Hamann B, Lederbogen F, et al. Antidepressant treatment with mirtazapine, but not venlafaxine, lowers cortisol concentrations in saliva: A randomised open trial. Psychiatry Res. 2010 ; 177: 109-113
140. Schroecksnadel K, Winkler C, Wirtleitner B, et al. Aspirin down-regulates tryptophan degradation in stimulated human peripheral blood mononuclear cells in vitro. Clin Exp Immunol. 2005 ; 140: 41-45
141. Schule C. Neuroendocrinological mechanisms of actions of antidepressant drugs. Neuroendocrinology. 2007 ; 19: 213-216
142. Shopsin B. Enhancement of the antidepressant response to L-tryptophan by a liver pyrrolase inhibitor: A rational treatment approach. Neuropsychobiology. 1978 ; 4: 188-192
143. Skelin I, Kikre-Merid M, Diksic M. Both acute and subchronic treatments with pindolol, a 5-HT (1A) and β1 and β2 adrenoceptor antagonist, elevate regional serotonin synthesis in the rat brain: An autoradiographic study. Neurochem Int. 2012 ; 61: 1417-1423
144. Stassen HH, Angst J, Delini-Stula A. Delayed onset of action of antidepressant drugs? Survey of recent results. Eur Psychiatry. 1997 ; 12: 166-176
145. Stassen HH, Angst J, Hell D, et al. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. J Clin Psychiatry. 2007 ; 68: 1195-1205
146. Stokes PE, Sikes CR Psychopharmacology: The Third Generation of Progress. Meltzer HY, ed. New York: Raven Press ; 1987: 589-607.
147. Stokes PE, Maas JW, Davis JM, et al. Biogenic amine and metabolite levels in depressed patients with high versus normal hypothalamic-pituitary- Adrenocortical activity. Am J Psychiatry. 1987 ; 144: 868-872
148. Sze PY, Neckers L, Towle AC. Glucocorticoids as a regulatory factor for brain tryptophan hydroxylase. J Neurochem. 1976 ; 26: 169-173
149. Taylor MW, Feng G. Relationship between interferon-γ, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 1991 ; 5: 2516-2522
150. Taymur I, Ozen NE, Boratav RC, et al. Urinary neopterin levels in patients with major depressive disorder and panic disorder who do not receive pharmacologic treatment. Anatolian J Psychiatry. 2011 ; 12: 7-12
151. Thompson J, Rankin H, Ashcroft GW, et al. The treatment of depression in general practice: A comparison of L-tryptophan, amitriptyline, and a combination of L-tryptophan and amitriptyline with placebo. Psychol Med. 1982 ; 12: 741-751
152. Tiemeier H, Fekkes D, Hofman A, et al. Plasma pterins and folate in late life depression: The Rotterdam Study. Psychiatry Res. 2006 ; 145: 199-206
153. Torrente M, Gelenberg AJ, Vrana KE. Boosting serotonin in the brain: Is it time to revamp the treatment of depression?. J Psychopharmacol. 2012 ; 26: 629-635
154. Turner EH, Loftis JM, Blackwell AD. Serotonin a la carte: Supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacol Ther. 2006 ; 109: 325-338
155. Uher R, Mors O, Rietschel M, et al. Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: A secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. J Clin Psychiatry. 2011 ; 72: 1478-1484
156. Wachter H, Fuchs D, Hausen A, et al. Neopterin as marker of activation of cellular immunity: Immunologic basis and clinical application. Adv Clin Chem. 1989 ; 27: 81-141
157. Warriner EM, Rourke SB, Rourke BP, et al. Immune activation and neuropsychiatric symptoms in HIV infection. J Neuropsychiat Clin Neurosci. 2010 ; 22: 321-328
158. Weber CC, Eckert GP, Muller WE. Effects of antidepressants on the brain/plasma distribution of corticosterone. Neuropsychopharmacology. 2006 ; 31: 2443-2448
159. Weiss G, Murr C, Zoller H, et al. Modulation of neopterin formation and tryptophan degradation by Th1- and Th2-derived cytokines in human monocytic cells. Clin Exp Immunol. 1999 ; 116: 435-440
160. Werner ER, Bitterlich G, Fuchs D, et al. Human macrophages degrade tryptophan upon induction by interferon-gamma. Life Sci. 1987 ; 41: 273-280
161. Werner ER, Fuchs D, Hausen A, et al. Tryptophan degradation in patients infected by human immunodeficiency virus. Biol Chem Hoppe-Seyler. 1988 ; 369: 337-340
162. Werner ER, Werner-Felmayer G, Fuchs D, et al. Parallel induction of tetrahydrobiopterin biosynthesis and indoleamine 2,3-dioxygenase activity in human cells and cell lines by interferon-gamma. Biochem J. 1989 ; 262: 861-866
163. Werner ER, Werner-Felmayer G, Fuchs D, et al. Tetrahydrobiopterin biosynthetic activities in human macrophages, fibroblasts, TPH-1 and T 24 cells: GTP cyclohydrolase-1 is stimulated by interferon gamma, and 6-pyruvoyl tetrahydrobiopterin synthase and sepiapterin are constitutively present. J Biol Chem. 1990 ; 265: 3189-3192
164. Winge I, McKinney JA, Ying M, et al. Activation and stabilisation of human tryptophan hydroxylase 2 by phosphorylation and 14-3-3 binding. Biochem J. 2008 ; 410: 195-204
165. Wolkowitz OM, Reus VI. Treatment of depression with antiglucocorticoid drugs. Psychosomatic Med. 1999 ; 61: 698-711
166. Wood K, Harwood J, Swade C, et al. Decreased tryptophan excretion by depressive patients. Clin Chim Acta. 1978 ; 88: 57-61
167. Wurtman RJ, Hefti F, Melamed E. Precursor control of neurotransmitter synthesis. Pharmacol Rev. 1981 ; 32: 315-335
168. Yamazaki F, Kuroiwa T, Takikawa O, et al. Human indolylamine 2,3-dioxygenase: Its tissue distribution, and characterization of the placental enzyme. Biochem J. 1985 ; 230: 635-638
169. Yoshida R, Hayaishi O. Induction of pulmonary indoleamine 2,3-dioxygenase by intraperitoneal injection of bacterial lipopolysaccharide. Proc Natl Acad Sci USA. 1978 ; 75: 3998-4000
170. Young SN. Mechanism of decline in rat brain 5-hydroxytryptamine after induction of liver tryptophan pyrrolase by hydrocortisone: Roles of tryptophan catabolism and kynurenine synthesis. Br J Pharmacology. 1981 ; 74: 695-700
171. Young SN, Sourkes TL. Tryptophan catabolism by tryptophan pyrrolase in rat liver. J Biol Chem. 1975 ; 250: 5009-5014
172. Yuwiler A, Brammar GL, Morley JE, et al. Short-term and repetitive administration of oral tryptophan in normal men. Arch Gen Psychiatry. 1981 ; 38: 619-626
173. Zmilacher K, Battegay R, Gastpar M. L-5-Hydroxytryptophan alone and in combination with a peripheral decarboxylase inhibitor in the treatment of depression. Neuropsychobiology. 1988 ; 20: 28-35